ZYBERNO
Stock Report
Updated Sep 1, 2026

DARE BIOSCIENCE, INC. (DARE)

Healthcare • NASDAQ

$0.76

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
11.0/100
POOR BUSINESS
DARE BIOSCIENCE, INC. (DARE) scores 11/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-748.1%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-813.4%)
Return on Capital (Capital Efficiency):CRITICAL (-85.4%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

DARE BIOSCIENCE, INC. (DARE) stock report — Zyberno Score 11/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, DARE generated -$10.47M in Owner Earnings. Capital was deployed as follows: $227.95K invested in capital expenditures. Reinvestment rate: 15.0%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.76
Market Cap:$11.33M

Valuation Multiples (2)

P/S Ratio:8.30x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$176.43K

Price Action & Momentum (3)

Momentum Percentile:27 / 100
% of 52-Week High:20.1%
B. Profitability Assessment

Return Metrics (5)

ROA:-38.7%
Reinvestment Rate:15.0%
Fundamental Growth Rate (g):-12.8%

Margin Analysis (3)

Operating Margin Ttm:-813.4%
Net Margin Ttm:-804.4%
Ebitda Margin:-664.7%

TTM Performance (2)

Operating Margin Ttm:-813.4%
Net Margin Ttm:-804.4%

Yield Metrics (2)

Earnings Yield:-$176.03
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:61.7%
Latest Earnings Filed:2026-08-13

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-50.0%

Cash Flow Growth (Linear) (2)

Free Cash Flow Growth Rate (Linear):-42.5%
Operating Cash Flow Growth Rate (Linear):-39.7%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.99x
Quick Ratio:0.99x
Cash Ratio:0.75x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:-236,457.00
Cash And Cash Equivalents:12,617,594.00
Long Term Debt:$868.37K
Net Debt:-$11.15M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $1.37M
Linear Growth: -50.0%
📊 Click to view full DARE Revenue analysis & methodology →
Cost Of Revenue Ttm:$295.80K

Profitability Breakdown (2)

$734.39K-$11.11M

Bottom Line Performance (3)

-$10.99M
Income Before Tax:-$13.54M
Ebitda Ttm:-9,079,275.00

Operating Expenses (5)

Operating Expenses:11,618,220.00
R And D Expense:2,699,637.00
Sga Expense:8,918,583.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:1,439.5%
Sga To Revenue Percentage:4,755.4%
Ebitda Margin:-664.7%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$22.37M
Current Assets:$16.69M
Ppe Net:1,419,796.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:22,930,209.00
Current Liabilities:16,922,620.00
Long Term Debt:$868.37K
Short Term Debt:$594.49K

Equity & Capital (3)

Equity:-$560.10K
Retained Earnings:-$194.67M
Common Stock:240,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:762,914.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:286,602.00
C. Cash Flow Analysis

Operating Activities (2)

Operating cash flow TTM: -$9.94M
Linear Growth: -39.7%
Free cash flow TTM: -$10.16M
Linear Growth: -42.5%
📊 Click to view full DARE Free Cash Flow analysis & methodology →

Investment Activities (2)

Investing Cash Flow:$0.00
Capital Expenditures Ttm:227,947.00

Financing Activities (3)

Financing Cash Flow:-$715.47K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:94,887.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:2,031,019.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.61
-$1.61
Earnings Per Share Ttm:-$0.74

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.09
Operating Cash Flow Per Share:-$0.66

Book Value & Capital (2)

Book Value Per Share:-$0.04
Cash Per Share:0.85

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.05x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:941.39
Cash Conversion Cycle:-2,939.39
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$10.47M

Damodaran Growth Analysis (2)

Reinvestment Rate:15.0%
Fundamental Growth Rate (g):-12.8%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-50.0%

Cash Flow Growth Rates (2)

Free Cash Flow Growth Rate (Linear):-42.5%
Operating Cash Flow Growth Rate (Linear):-39.7%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-50.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:DARE
Company Name:DARE BIOSCIENCE, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:14.89M
Shares Outstanding Basic:14.89M
Shares Outstanding Diluted:14.89M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 08:32:49 UTC
Data Timestamp:2026-08-20T21:40:42.065940
Scroll to Top